Keywords: cv, therapeutics, soars, ranolazine, data, seen, its

CV Therapeutics soars on ranolazine data

Article | 23 August 1999

Print This

CV Therapeutics has seen its stock price soar recently on the back ofinitial data from its Phase III trial of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in